Menu Search
Equities

Crescita Therapeutics Inc

CRRTF:PKC

Crescita Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.449
  • Today's Change0.00 / 0.00%
  • Shares traded61.00
  • 1 Year change+60.36%
  • Beta--
Data delayed at least 15 minutes, as of Oct 17 2024 15:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.

  • Revenue in CAD (TTM)17.40m
  • Net income in CAD-2.74m
  • Incorporated2016
  • Employees80.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CTX:TOR since
announced		Transaction
value
Occy Laboratory Inc-Non-Real Estate Business AssetsDeal completed20 Jun 202420 Jun 2024Deal completed35.71%657.00k
Data delayed at least 15 minutes, as of Nov 14 2024 18:39 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.